Christopher Dinsmore - 07 Sep 2021 Form 4 Insider Report for Kronos Bio, Inc. (KRON)

Role: Chief Scientific Officer
Signature: /s/ Allison Frisbee, Attorney-in-Fact
Issuer symbol: KRON
Transactions as of: 07 Sep 2021
Net transactions value: -$171,254
Form type: 4
Filing time: 09 Sep 2021, 13:23:42 UTC
Previous filing: 03 Aug 2021
Next filing: 04 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRON	Common Stock	Options Exercise	$30,048	+9,189	+9.5%	$3.27	105,549	07 Sep 2021	Direct
transaction	KRON	Common Stock	Sale	$201,302	-9,189	-8.7%	$21.91^*	96,360	07 Sep 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRON	Employee Stock Option (Right to Buy)	Options Exercise	$0	-9,189	-2.8%	$0.000000	324,497	07 Sep 2021	Common Stock	9,189	$3.27	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2021.
F2	The weighted average sale price for the transaction reported was $21.9068, and the range of prices were between $20.85 and $22.78. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3	Immediately exercisable.